LAM-001 for lung transplant patients with BOS
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a double lung transplant at least 12 months ago.
- Your lung function (FEV1) has dropped to between 51% and 85% of your best measurements, and this drop has lasted over 30 days.
- You have been diagnosed with BOS within the last 12 months.
- You are on a stable regimen of three standard anti-rejection medicines (prednisone plus mycophenolate or azathioprine plus tacrolimus or cyclosporine).
- You have not taken sirolimus or everolimus in the last 4 weeks.
- You are well enough to undergo routine bronchoscopy (a scope down your airway to look at your lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
This study collects tiny airway samples during a planned bronchoscopy to better understand bronchiolitis obliterans (a long-term lung complication after transplant). Your samples may help researchers learn how the disease starts and changes over time.
This trial tests whether a single dose of stem cells given through a bronchoscope is safe for people whose lungs are failing after a transplant. It may help those with a condition called bronchiolitis obliterans syndrome (BOS), a type of chronic rejection that makes it harder to breathe.
This trial tests nintedanib to slow or improve bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a hematopoietic stem cell transplant. You may be considered if your breathing tests and scans show BOS, and if active infections and certain health risks are ruled out.
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
This trial tests an oral medication called belumosudil for people with chronic lung allograft dysfunction (CLAD) after a double lung transplant. It may help slow the decline in lung function.
Hear when a new Bronchiolitis Obliterans Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.